Objective Cystic Fibrosis (CF) is a chronically debilitating and life threatening medical condition. Respiratory insufficiency and complications of chronic lung infection lead to long term reduction in quality of life and health and even to premature death. Chronic bacterial infections with Pseudomonas aeruginosa (PA), Staphylococcus aureus and Haemophilus influezae are typical for CF and repeated courses of antibiotics in heavy doses has more than doubled the median survival age. No preventive or eradicative treatments of PA infection in the lungs exist today. The most significant bacterial pathogen associated with CF pulmonary disease is PA. PA is an opportunistic, life-threatening gram-negative bacteria which produces various immune modulatory products enabling it to survive in the lungs and cause morbidity and mortality. CF patients are particularly at risk of infection due to the viscous mucus lining their airways, which compromises their respiratory function.The European Medicines Agency granted “Anti-pseudomonas IgY” an Orphan Drug Designation in September 2008, and paediatric CF product development was encouraged. The IMPACTT project will perform a clinical phase III trial, to demonstrate the critical preventive and therapeutic effects of this pioneering intervention therapy for the fatal chronic infection of Pseudomonas aeruginosa in CF patients. The project mobilises the critical mass of experts from academia, patient organisations, clinical trials managers, clinicians and industry aiming to eradicate PA infection in CF patient lungs and thereby alleviate the negative impact of PA on the quality of life of CF patients and their families.Despite good results with antibiotics, continuous pulmonary deterioration and death of the CF patient is a reality. Alternative therapeutic strategies are badly needed. Our phase I and II clinical studies prove that a single daily gargle with the proposed Anti-Pseudomonas IgY solution significantly improves the condition. Fields of science social sciencessociologydemographymortalitynatural sciencesbiological sciencesmicrobiologybacteriologymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Topic(s) HEALTH.2010.2.4.4-1 - Clinical development of substances with a clear potential as orphan drugs. FP7-HEALTH-2010-single-stage Call for proposal FP7-HEALTH-2010-single-stage See other projects for this call Funding Scheme CP-FP - Small or medium-scale focused research project Coordinator UPPSALA UNIVERSITET EU contribution € 570 971,60 Address VON KRAEMERS ALLE 4 751 05 Uppsala Sweden See on map Region Östra Sverige Östra Mellansverige Uppsala län Activity type Higher or Secondary Education Establishments Administrative Contact Anders Larsson (Prof.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data Participants (9) Sort alphabetically Sort by EU Contribution Expand all Collapse all Immun System I.M.S. AB Sweden EU contribution € 1 980 700,00 Address Dag Hammerskjoelds Vaeg 26 75183 UPPSALA See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Hans Kollberg (Prof.) Links Contact the organisation Opens in new window Total cost No data MUKOVISZIDOSE INSTITUT - GEMEINNÜTZIGE GESELLSCHAFT FUR FORSCHUNG UND THERAPIEENTWICKLUNG Germany EU contribution € 1 305 000,00 Address IN DEN DAUEN 6 53117 BONN See on map Activity type Research Organisations Administrative Contact Andreas Reimann (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data REGION HOVEDSTADEN Denmark EU contribution € 469 280,00 Address KONGENS VAENGE 2 3400 Hillerod See on map Region Danmark Hovedstaden Nordsjælland Activity type Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments) Administrative Contact Bjarnsholt Thomas (Prof.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data VALSTYBINIS MOKSLINIU TYRIMU INSTITUTAS INOVATYVIOS MEDICINOS CENTRAS Lithuania EU contribution € 90 000,00 Address ZYGIMANTU 9 01102 Vilnius See on map Region Lietuva Sostinės regionas Vilniaus apskritis Activity type Other Administrative Contact Algirdas Venalis (Prof.) Links Contact the organisation Opens in new window Total cost No data CYSTIC FIBROSIS EUROPE EV Germany EU contribution € 113 520,36 Address IN DEN DAUEN 6 53117 Bonn See on map Region Nordrhein-Westfalen Köln Bonn, Kreisfreie Stadt Activity type Other Administrative Contact Birgit Dembski (Mrs.) Links Contact the organisation Opens in new window Total cost No data HEINRICH-HEINE-UNIVERSITAET DUESSELDORF Germany EU contribution € 625 900,00 Address UNIVERSITAETSSTRASSE 1 40225 Dusseldorf See on map Region Nordrhein-Westfalen Düsseldorf Düsseldorf, Kreisfreie Stadt Activity type Higher or Secondary Education Establishments Administrative Contact Christian Ohmann (Prof.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data REGION STOCKHOLM Sweden EU contribution € 78 600,00 Address HANTVERKARGATAN 45 104 22 Stockholm See on map Region Östra Sverige Stockholm Stockholms län Activity type Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments) Administrative Contact Anna Käll (Ms.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Participation ended France EU contribution € 19 408,04 Address RUE DE TOLBIAC 101 75654 Paris See on map Region Ile-de-France Ile-de-France Paris Activity type Research Organisations Administrative Contact Annick Bertault (Ms.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data CONSORZIO ITALIANO PER LA RICERCA IN MEDICINA (C.I.R.M.) Italy EU contribution € 122 800,00 Address VIALE ORTLES 22/4 20139 MILANO MI See on map Region Nord-Ovest Lombardia Milano Activity type Research Organisations Administrative Contact Alfonso Sassun (Mr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data